1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
About
Marko A. Mychaskiw, PhD, is affiliated with Teva Branded Pharmaceutical Products R&D, Inc., Global Health Economics and Outcomes Research in West Chester, Pennsylvania. His publications focus on schizophrenia and schizoaffective disorders, specifically exploring treatment pathways and factors influencing the initiation of atypical long-acting injectable antipsychotic agents in early-phase schizophrenia. He has collaborated frequently with co-authors including John M. Kane, Jose M. Rubio, Marc Tian, Mark Suett, and Sangtaeck Lim.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
